JP2020532542A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020532542A5 JP2020532542A5 JP2020512549A JP2020512549A JP2020532542A5 JP 2020532542 A5 JP2020532542 A5 JP 2020532542A5 JP 2020512549 A JP2020512549 A JP 2020512549A JP 2020512549 A JP2020512549 A JP 2020512549A JP 2020532542 A5 JP2020532542 A5 JP 2020532542A5
- Authority
- JP
- Japan
- Prior art keywords
- coor
- alkyl
- halogen
- amino
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 48
- 229910052736 halogen Inorganic materials 0.000 claims 45
- 150000002367 halogens Chemical class 0.000 claims 45
- 150000001875 compounds Chemical class 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 17
- 229910052799 carbon Inorganic materials 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- -1 6-amino-9H-purine-9-yl Chemical group 0.000 claims 12
- 229910052760 oxygen Inorganic materials 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 8
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims 8
- 125000000107 disulfanyl group Chemical group [*]SS[H] 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 4
- WYCJWOAQAMWVLL-UHFFFAOYSA-N octadecane-3,12-dione Chemical compound CCC(CCCCCCCCC(CCCCCC)=O)=O WYCJWOAQAMWVLL-UHFFFAOYSA-N 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 229960003301 nivolumab Drugs 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 0 CC*(C)C(C1)C1(CC1)O[C@]1*(C)CC Chemical compound CC*(C)C(C1)C1(CC1)O[C@]1*(C)CC 0.000 description 1
- KKOXZFIROVCRBT-PTIXEKJTSA-N Nc1ncnc2c1nc[n]2C[C@@H]([C@@H]1F)O[C@H](COP(O)(O[C@H]2C([n]3nnc4c3cccc4C(F)(F)F)O[C@H](CO3)[C@H]2O)S)[C@H]1O[P@]3(S)=O Chemical compound Nc1ncnc2c1nc[n]2C[C@@H]([C@@H]1F)O[C@H](COP(O)(O[C@H]2C([n]3nnc4c3cccc4C(F)(F)F)O[C@H](CO3)[C@H]2O)S)[C@H]1O[P@]3(S)=O KKOXZFIROVCRBT-PTIXEKJTSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762552689P | 2017-08-31 | 2017-08-31 | |
| US62/552,689 | 2017-08-31 | ||
| PCT/US2018/048662 WO2019046498A1 (en) | 2017-08-31 | 2018-08-30 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020532542A JP2020532542A (ja) | 2020-11-12 |
| JP2020532542A5 true JP2020532542A5 (OSRAM) | 2021-09-24 |
| JP7209697B2 JP7209697B2 (ja) | 2023-01-20 |
Family
ID=63529006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020512549A Active JP7209697B2 (ja) | 2017-08-31 | 2018-08-30 | 抗癌剤としての環状ジヌクレオチド |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10947263B2 (OSRAM) |
| EP (1) | EP3676278B1 (OSRAM) |
| JP (1) | JP7209697B2 (OSRAM) |
| KR (1) | KR102651946B1 (OSRAM) |
| CN (1) | CN111051327B (OSRAM) |
| ES (1) | ES2945140T3 (OSRAM) |
| WO (1) | WO2019046498A1 (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11660311B2 (en) | 2017-10-10 | 2023-05-30 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| WO2019123340A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| ES2980374T3 (es) * | 2018-03-08 | 2024-10-01 | Bristol Myers Squibb Co | Dinucleótidos cíclicos como agentes anticancerosos |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| CN112236438B (zh) * | 2018-04-13 | 2024-10-15 | 百时美施贵宝公司 | 基于磷(v)的试剂，其制备方法，以及其在制备立体限定的有机磷(v)化合物中的用途 |
| KR20210015937A (ko) | 2018-06-01 | 2021-02-10 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 방광암을 치료하기 위한 방법 |
| US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
| AU2019371206A1 (en) | 2018-10-29 | 2021-05-27 | Venenum Biodesign, LLC | Novel sting agonists |
| WO2020212600A1 (en) | 2019-04-18 | 2020-10-22 | Nuseed Global Innovation Ltd. | Meal fraction of brassica carinata oilseed |
| WO2020227421A1 (en) | 2019-05-09 | 2020-11-12 | Aligos Therapeutics, Inc. | Modified cyclic dinucleoside compounds as sting modulators |
| TW202114710A (zh) * | 2019-07-25 | 2021-04-16 | 英屬開曼群島商百濟神州有限公司 | 作為sting促效劑之環狀二核苷酸 |
| CN115244061A (zh) * | 2020-01-16 | 2022-10-25 | 百时美施贵宝公司 | 试剂及其用于模块化对映发散性合成c-p键的用途 |
| EP4134098A4 (en) | 2020-04-10 | 2024-05-15 | ONO Pharmaceutical Co., Ltd. | Method of cancer therapy |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| CA2602777C (en) | 2005-03-25 | 2018-12-11 | Tolerrx, Inc. | Gitr binding molecules and uses therefor |
| BR122020016659B8 (pt) | 2005-05-10 | 2021-07-27 | Incyte Holdings Corp | moduladores de 2,3-dioxigenase de indolamina e métodos de modulação de atividade de inibição e de imunossupressão |
| ES2540561T3 (es) | 2005-12-20 | 2015-07-10 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa |
| US20080125470A1 (en) | 2006-09-19 | 2008-05-29 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| DK2175884T3 (en) | 2007-07-12 | 2016-09-26 | Gitr Inc | Combination USING GITR BINDING MOLECULES |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| WO2009073620A2 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics | Ido inhibitors |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| SG178991A1 (en) | 2009-09-03 | 2012-04-27 | Schering Corp | Anti-gitr antibodies |
| US8722720B2 (en) | 2009-10-28 | 2014-05-13 | Newlink Genetics Corporation | Imidazole derivatives as IDO inhibitors |
| SI2949670T1 (sl) | 2009-12-10 | 2019-05-31 | F. Hoffmann-La Roche Ag | Protitelesa, ki se preferenčno vežejo na zunajcelično domeno 4 človeškega CSF1R, in njihova uporaba |
| SG10201604336VA (en) | 2010-03-04 | 2016-07-28 | Macrogenics Inc | Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| MX2012010014A (es) | 2010-03-05 | 2012-09-21 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| ES2706412T3 (es) | 2010-05-04 | 2019-03-28 | Five Prime Therapeutics Inc | Anticuerpos que se unen a CSF1R |
| CA2810359C (en) | 2010-09-09 | 2021-06-22 | Pfizer Inc. | 4-1bb binding molecules |
| NO2694640T3 (OSRAM) | 2011-04-15 | 2018-03-17 | ||
| ES2669310T3 (es) | 2011-04-20 | 2018-05-24 | Medimmune, Llc | Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1 |
| MX356337B (es) | 2011-12-15 | 2018-05-23 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| CN104093740B (zh) | 2012-02-06 | 2018-01-09 | 弗·哈夫曼-拉罗切有限公司 | 使用csf1r抑制剂的组合物和方法 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| KR20150018533A (ko) | 2012-05-11 | 2015-02-23 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법 |
| US9175082B2 (en) | 2012-05-31 | 2015-11-03 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| KR20150047593A (ko) | 2012-08-31 | 2015-05-04 | 파이브 프라임 테라퓨틱스, 인크. | 집락 자극 인자 1 수용체(csf1r)에 결합하는 항체로 질환을 치료하는 방법 |
| CA2908154C (en) * | 2013-04-29 | 2023-11-28 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
| SG11201508528TA (en) | 2013-05-02 | 2015-11-27 | Anaptysbio Inc | Antibodies directed against programmed death-1 (pd-1) |
| JP6400082B2 (ja) * | 2013-05-18 | 2018-10-03 | アデュロ バイオテック，インコーポレイテッド | 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を抑制するための組成物および方法 |
| RS59500B1 (sr) * | 2013-05-18 | 2019-12-31 | Aduro Biotech Inc | Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“ |
| CN111423511B (zh) | 2013-05-31 | 2024-02-23 | 索伦托药业有限公司 | 与pd-1结合的抗原结合蛋白 |
| PT3702373T (pt) | 2013-09-13 | 2022-09-27 | Beigene Switzerland Gmbh | Anticorpos anti-pd1 e a sua utilização como agentes terapêuticos e de diagnóstico |
| JP2016538344A (ja) * | 2013-11-19 | 2016-12-08 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | 癌処置としてのｓｔｉｎｇアゴニストの使用 |
| CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| HK1247089A1 (zh) * | 2015-03-10 | 2018-09-21 | Aduro Biotech, Inc. | 用於活化“干扰素基因刺激物”依赖性信号传导的组合物和方法 |
| JP6826055B2 (ja) | 2015-03-13 | 2021-02-03 | サイトメックス セラピューティクス インコーポレイテッド | 抗ｐｄｌ１抗体、活性化可能抗ｐｄｌ１抗体、およびその使用方法 |
| GEP20207182B (en) * | 2015-08-13 | 2020-11-25 | Merck Sharp & Dohme | Cyclic di-nucleotide compounds as sting agonists |
| UY36969A (es) * | 2015-10-28 | 2017-05-31 | Novartis Ag | Composiciones y métodos para activar la señalización dependiente del estimulador del gen de interferon |
| MX363780B (es) * | 2015-12-03 | 2019-04-03 | Glaxosmithkline Ip Dev Ltd | Dinucleótidos de purina cíclica como moduladores del estimulador de los genes de interferón. |
| DE212016000029U1 (de) * | 2015-12-07 | 2017-07-30 | Opi Vi - Ip Holdco Llc | Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten |
| WO2017106740A1 (en) * | 2015-12-16 | 2017-06-22 | Aduro Biotech, Inc. | Methods for identifying inhibitors of "stimulator of interferon gene"-dependent interferon production |
| WO2017123657A1 (en) * | 2016-01-11 | 2017-07-20 | Gary Glick | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer |
| US11685761B2 (en) * | 2017-12-20 | 2023-06-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
-
2018
- 2018-08-30 ES ES18766542T patent/ES2945140T3/es active Active
- 2018-08-30 WO PCT/US2018/048662 patent/WO2019046498A1/en not_active Ceased
- 2018-08-30 US US16/641,679 patent/US10947263B2/en active Active
- 2018-08-30 EP EP18766542.7A patent/EP3676278B1/en active Active
- 2018-08-30 JP JP2020512549A patent/JP7209697B2/ja active Active
- 2018-08-30 KR KR1020207008757A patent/KR102651946B1/ko active Active
- 2018-08-30 CN CN201880055306.3A patent/CN111051327B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020532542A5 (OSRAM) | ||
| JP2020532529A5 (OSRAM) | ||
| JP2020532539A5 (OSRAM) | ||
| JP2020536971A5 (OSRAM) | ||
| JP2020529400A5 (OSRAM) | ||
| JP2019501204A5 (OSRAM) | ||
| JP2020536897A5 (OSRAM) | ||
| JP2021500926A5 (OSRAM) | ||
| IL286846B1 (en) | History of Camptothecin | |
| JP2020506951A5 (OSRAM) | ||
| JP2019535746A5 (OSRAM) | ||
| JP2016512223A5 (OSRAM) | ||
| JP2018504418A5 (OSRAM) | ||
| JP2020531447A5 (OSRAM) | ||
| JP2019535744A5 (OSRAM) | ||
| JP2018535692A5 (OSRAM) | ||
| IL273387B2 (en) | Thylanstatin analogs | |
| JP2013512263A5 (OSRAM) | ||
| RU2014127753A (ru) | Ингибиторы пути передачи сигнала notch и их применение при лечении рака | |
| JP2011512332A5 (OSRAM) | ||
| JP2013503824A5 (OSRAM) | ||
| JP2010540556A5 (OSRAM) | ||
| CN104936956A (zh) | 氨基取代的异噻唑 | |
| HRP20220520T1 (hr) | Ciklički dinukleotidi kao agensi protiv raka | |
| JPWO2019214634A5 (OSRAM) |